Abstract:Background Antiphospholipid syndrome (APS) is an autoimmune disease characterised mainly by arterial and/or venous thrombosis, recurrent pregnancy morbidity, with the presence of a variety of heterogeneous circulating antiphospholipid antibodies. However, there are a group of APS patients with persistently negative antiphospholipid antibodies. It is necessary to validate new specific antibodies to better recognition of these APS patients. Objectives To explore the clinical significance of non-criteria anti-phospholipid antibodies in a large cohort of Chinese patients with anti-phospholipid syndrome (APS). Methods Serum samples were obtained from 214 APS patients, 122 disease control including systemic lupus erythematosus, sjogren syndrome, ankylosing spondylitis, rheumatoid arthritis, osteoarthritis and 50 healthy control. Antiphosphatidylserine(IgA/IgG/IgM) (aPS), anti-phosphatidylethanolamine (IgA/IgG/IgM) (aPE), anti-prothrombin-antibodies (IgA/IgG/IgM) (aPT) , anti-annexin V-antibodies (IgA/IgG/IgM) (aAnxV), anti-phosoholipid-antibody(IgG/IgM)(aPL), anti-oxLDL antibody(IgG/IgM)(aoxLDL) were tested by ELISA kits(HUMAN Diagnostics Products, Germany) and IgG/IgM APhL were tested by ELISA(Louisville APL Diagnostic, USA). The Chi-square (χ2) test was used to examine the difference of frequencies of antibodies in APS patients and patients with other diseases. Spearman correlation analysis was performed to investigate the relationship between aPS/PT and other clinical/laboratory parameters. Results The prevalence of aPS IgG, aPS IgM, aPT, aPE, aAnxV, aPL, aoxLDL and IgG APhL, IgM APhL were 44.8%, 22.4%, 46.3%, 9.8%, 17.8%, 44.4%, 22.4%, 45.3% and 22.9%. The specificity of the antibodies were 82.6%, 95.3%, 96.0%, 99.4%, 95.3%, 92.4%, 87.2%, 95.3% and 94.8%. The highest positive predictive values of these antibodies were aPE. aPE, aPS IgM and APhL IgM were associated with thrombotic events and oxLDL, aPE, aPL, aPS IgG, aPS IgM, aPT, aoxLDL, APhL IgG and APHL IgM were correlated with anti-cardiolipin antibody(ACL). aPL, aPS IgG, aPS IgM, aPT, APhL IgG and APhL IgM were associated with β2-GP1 antibody. APhL IgG, APhL IgM and PS IgG were the highest prevalence in both ACL and lupus anticoagulant (LAC) negative patients. aPT has the highest prevalence in ACL and β2-GP1 negative patients and APhL IgG and aPS IgG were the highest two antibodies in LAC and β2-GP1 negative patients and aPT has the highest prevalence in seronegative APS patients. Conclusions Non-criteria aPLs have a good diagnostic value in APS and were associated with thrombotic events. References [1] Hughes GR, Khamashta MA (2003) Seronegative antiphospholipid syndrome. Ann Rheum Dis62:1127 [2] Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.Rheumatology2015;54:2042–2050. [3] A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus2017;26(6):606–615. Acknowledgements We thank all patients and healthy donors whom took part in this study. Disclosure of Interest None declared

Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls

An Intestinal Microbiome Intervention Affects Biochemical Disease Activity in Patients with Antiphospholipid Syndrome

[The role of the microbiome in lupus and antiphospholipid syndrome]

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study

Gut Microbiota in Systemic Lupus Erythematosus: A Fuse and a Solution

Compositional and functional aberrance of the gut microbiota in treatment-naïve patients with primary Sjögren's syndrome

An immunogenomic exome landscape of triple positive primary antiphospholipid patients

Identification of common MicroRNAs expression signatures in antiphospholipid syndrome and thromboembolic disease: A scoping review

Deciphering the clinical significance of longitudinal antiphospholipid antibody titers

Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome

Anti-{beta}2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China

Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus

AB0559 the Prevalence of Non-Criteria Anti-Phospholipid Antibodies in Anti-Phospholipid Syndrome

Anti-β2GPI-domain I Antibody is Associated with Extra-Criteria Manifestations in a Large Prospective Antiphospholipid Syndrome Cohort in China.

A qualitative investigation of the experiences of patients living with antiphospholipid antibodies

Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome

A Scoping Review of the Positive and Negative Bacteria Associated With the Gut Microbiomes of Systemic Lupus Erythematosus Patients

Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression